DexCom Inc
Cerrado
SectorSanidad
69.73 1.19
Resumen
Variación precio
24h
Mínimo
68.85
Máximo
71.01
Ingresos | -68M 200M |
|---|---|
Ventas | -68M 1.2B |
P/B Media del Sector | 29.644 50.958 |
BPA | 0.56 |
Margen de beneficios | 16.738 |
Empleados | 11,000 |
EBITDA | -52M 337M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +19.86% upside |
Próximas Ganancias | 29 jul 2026 |
|---|
Capitalización Mercado | 3B 27B |
|---|---|
Apertura anterior | 68.54 |
Cierre anterior | 69.73 |
Noticias sobre sentimiento de mercado
By Acuity
18%
82%
35 / 342 Clasificación en Healthcare
DexCom Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.